| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 42 | 2025 | 225 | 10.790 |
Why?
|
| Prostatic Neoplasms | 39 | 2024 | 995 | 6.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2024 | 1559 | 4.420 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 19 | 2024 | 45 | 3.920 |
Why?
|
| Antineoplastic Agents | 29 | 2025 | 2044 | 3.760 |
Why?
|
| Kidney Neoplasms | 23 | 2023 | 346 | 3.750 |
Why?
|
| Carcinoma, Transitional Cell | 13 | 2025 | 59 | 3.420 |
Why?
|
| Carcinoma, Renal Cell | 18 | 2023 | 177 | 3.340 |
Why?
|
| Neoadjuvant Therapy | 11 | 2024 | 378 | 2.670 |
Why?
|
| Androgen Antagonists | 15 | 2024 | 79 | 2.570 |
Why?
|
| Prednisone | 15 | 2024 | 236 | 1.970 |
Why?
|
| Cisplatin | 14 | 2024 | 298 | 1.920 |
Why?
|
| Pyrroles | 7 | 2017 | 201 | 1.630 |
Why?
|
| Neoplasm Invasiveness | 9 | 2024 | 481 | 1.560 |
Why?
|
| Indoles | 7 | 2017 | 387 | 1.430 |
Why?
|
| Urologic Neoplasms | 6 | 2023 | 26 | 1.370 |
Why?
|
| Medical Oncology | 5 | 2020 | 267 | 1.370 |
Why?
|
| Taxoids | 8 | 2025 | 98 | 1.340 |
Why?
|
| Androstenes | 6 | 2024 | 17 | 1.320 |
Why?
|
| Abiraterone Acetate | 9 | 2021 | 14 | 1.310 |
Why?
|
| Neoplasm Metastasis | 24 | 2021 | 609 | 1.290 |
Why?
|
| Urothelium | 3 | 2016 | 37 | 1.270 |
Why?
|
| Neoplasm Staging | 14 | 2024 | 1281 | 1.230 |
Why?
|
| Male | 95 | 2025 | 63586 | 1.100 |
Why?
|
| Phenylurea Compounds | 6 | 2016 | 88 | 1.100 |
Why?
|
| Adenocarcinoma | 7 | 2020 | 889 | 1.100 |
Why?
|
| Mitoxantrone | 5 | 2018 | 14 | 1.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2017 | 155 | 1.070 |
Why?
|
| Prostate-Specific Antigen | 12 | 2024 | 159 | 1.060 |
Why?
|
| Humans | 136 | 2025 | 129527 | 1.020 |
Why?
|
| Aged | 60 | 2025 | 22063 | 1.010 |
Why?
|
| Cystectomy | 7 | 2024 | 37 | 1.010 |
Why?
|
| Niacinamide | 5 | 2016 | 75 | 1.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2025 | 755 | 1.000 |
Why?
|
| Orchiectomy | 4 | 2014 | 67 | 0.970 |
Why?
|
| Mineralocorticoids | 1 | 2024 | 8 | 0.920 |
Why?
|
| Aged, 80 and over | 29 | 2024 | 7052 | 0.900 |
Why?
|
| Carcinoma, Small Cell | 1 | 2024 | 169 | 0.880 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2025 | 125 | 0.870 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 7 | 0.840 |
Why?
|
| Phenylthiohydantoin | 7 | 2024 | 41 | 0.840 |
Why?
|
| Carcinoma | 2 | 2016 | 213 | 0.770 |
Why?
|
| Testicular Neoplasms | 3 | 2023 | 102 | 0.760 |
Why?
|
| Middle Aged | 49 | 2025 | 31087 | 0.740 |
Why?
|
| Nitriles | 11 | 2024 | 169 | 0.730 |
Why?
|
| ErbB Receptors | 6 | 2018 | 605 | 0.730 |
Why?
|
| Treatment Outcome | 29 | 2024 | 10232 | 0.720 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2014 | 885 | 0.700 |
Why?
|
| Immunotherapy | 5 | 2022 | 596 | 0.690 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2024 | 376 | 0.650 |
Why?
|
| Radiosurgery | 4 | 2015 | 321 | 0.630 |
Why?
|
| Prognosis | 13 | 2024 | 3772 | 0.630 |
Why?
|
| Disease-Free Survival | 12 | 2017 | 647 | 0.600 |
Why?
|
| Benzamides | 8 | 2024 | 203 | 0.580 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 229 | 0.580 |
Why?
|
| Sulfonamides | 2 | 2012 | 497 | 0.570 |
Why?
|
| Viscera | 2 | 2014 | 16 | 0.570 |
Why?
|
| Hematologic Diseases | 2 | 2016 | 61 | 0.560 |
Why?
|
| Prostatectomy | 5 | 2018 | 103 | 0.540 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 181 | 0.530 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2016 | 11 | 0.530 |
Why?
|
| Urinary Bladder | 3 | 2023 | 176 | 0.530 |
Why?
|
| Databases, Factual | 5 | 2024 | 1261 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1510 | 0.520 |
Why?
|
| Antibodies, Monoclonal | 6 | 2025 | 1366 | 0.500 |
Why?
|
| Receptors, Androgen | 2 | 2021 | 143 | 0.490 |
Why?
|
| BCG Vaccine | 3 | 2024 | 24 | 0.490 |
Why?
|
| Deoxycytidine | 4 | 2024 | 163 | 0.490 |
Why?
|
| Retrospective Studies | 16 | 2024 | 14532 | 0.490 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 635 | 0.480 |
Why?
|
| Pancreatitis | 1 | 2016 | 124 | 0.480 |
Why?
|
| Genomics | 2 | 2018 | 715 | 0.470 |
Why?
|
| Silymarin | 4 | 2013 | 199 | 0.460 |
Why?
|
| Leydig Cell Tumor | 1 | 2014 | 7 | 0.440 |
Why?
|
| Neoplasms | 3 | 2025 | 2450 | 0.420 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2016 | 201 | 0.410 |
Why?
|
| Multicenter Studies as Topic | 2 | 2021 | 287 | 0.400 |
Why?
|
| Pyrazoles | 3 | 2024 | 403 | 0.390 |
Why?
|
| Hypothyroidism | 1 | 2012 | 66 | 0.380 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 259 | 0.380 |
Why?
|
| Administration, Intravesical | 3 | 2022 | 15 | 0.380 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2013 | 74 | 0.380 |
Why?
|
| Adult | 28 | 2025 | 35505 | 0.370 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1684 | 0.370 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 17 | 0.370 |
Why?
|
| Diethylstilbestrol | 1 | 2011 | 9 | 0.370 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 70 | 0.370 |
Why?
|
| Angiomyolipoma | 1 | 2011 | 17 | 0.370 |
Why?
|
| Sarcoma | 1 | 2013 | 175 | 0.360 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 107 | 0.360 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.350 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 2342 | 0.340 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2008 | 596 | 0.340 |
Why?
|
| Disease Progression | 10 | 2021 | 2628 | 0.330 |
Why?
|
| Female | 30 | 2025 | 68650 | 0.330 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2010 | 65 | 0.330 |
Why?
|
| United States | 11 | 2024 | 13865 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 391 | 0.330 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 650 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2016 | 850 | 0.330 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 417 | 0.330 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2024 | 34 | 0.320 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 55 | 0.320 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 502 | 0.320 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2010 | 186 | 0.320 |
Why?
|
| SEER Program | 4 | 2023 | 202 | 0.310 |
Why?
|
| Lymphatic Diseases | 1 | 2009 | 21 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2009 | 78 | 0.310 |
Why?
|
| Cystitis | 1 | 2009 | 22 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2019 | 527 | 0.310 |
Why?
|
| Neuroblastoma | 1 | 2010 | 151 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 956 | 0.300 |
Why?
|
| Survival Rate | 9 | 2021 | 1870 | 0.300 |
Why?
|
| Androstadienes | 3 | 2013 | 106 | 0.290 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2008 | 21 | 0.290 |
Why?
|
| Muscles | 3 | 2024 | 320 | 0.290 |
Why?
|
| Intestinal Perforation | 1 | 2008 | 45 | 0.290 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2024 | 6 | 0.290 |
Why?
|
| Double-Blind Method | 12 | 2021 | 1873 | 0.290 |
Why?
|
| Precision Medicine | 1 | 2011 | 385 | 0.290 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 1001 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 628 | 0.280 |
Why?
|
| Pyrimidines | 1 | 2011 | 458 | 0.280 |
Why?
|
| Testosterone | 3 | 2021 | 371 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 2503 | 0.280 |
Why?
|
| Survival Analysis | 6 | 2021 | 1270 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 875 | 0.270 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 1159 | 0.260 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 1201 | 0.260 |
Why?
|
| Nanotubes | 2 | 2018 | 43 | 0.260 |
Why?
|
| Quinazolines | 4 | 2019 | 241 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2024 | 1257 | 0.250 |
Why?
|
| Doxorubicin | 2 | 2024 | 328 | 0.250 |
Why?
|
| Carboplatin | 1 | 2006 | 139 | 0.250 |
Why?
|
| Neoplasm Grading | 6 | 2018 | 283 | 0.250 |
Why?
|
| DNA Damage | 2 | 2024 | 383 | 0.250 |
Why?
|
| Gold | 2 | 2018 | 119 | 0.250 |
Why?
|
| Thiohydantoins | 2 | 2024 | 5 | 0.250 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 3181 | 0.240 |
Why?
|
| Vinca Alkaloids | 1 | 2025 | 5 | 0.240 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 830 | 0.240 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 319 | 0.240 |
Why?
|
| Bridged-Ring Compounds | 1 | 2025 | 13 | 0.240 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2020 | 203 | 0.240 |
Why?
|
| Recombinational DNA Repair | 1 | 2024 | 13 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 751 | 0.230 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2024 | 1 | 0.230 |
Why?
|
| Hypokalemia | 1 | 2024 | 24 | 0.230 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 5 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 1368 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 208 | 0.220 |
Why?
|
| Hematuria | 1 | 2024 | 12 | 0.220 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 627 | 0.220 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 65 | 0.220 |
Why?
|
| Societies, Medical | 2 | 2018 | 757 | 0.220 |
Why?
|
| Vinblastine | 1 | 2024 | 69 | 0.220 |
Why?
|
| Drug Synergism | 3 | 2011 | 370 | 0.220 |
Why?
|
| Dexamethasone | 1 | 2006 | 347 | 0.220 |
Why?
|
| Pharmacogenetics | 1 | 2025 | 172 | 0.210 |
Why?
|
| Androstenols | 3 | 2015 | 4 | 0.210 |
Why?
|
| Tosyl Compounds | 4 | 2018 | 15 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 2013 | 0.210 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 763 | 0.210 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 2 | 2014 | 5 | 0.200 |
Why?
|
| Vitamin D | 1 | 2006 | 379 | 0.200 |
Why?
|
| Methotrexate | 1 | 2024 | 248 | 0.200 |
Why?
|
| Anilides | 4 | 2018 | 70 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 32 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 1327 | 0.200 |
Why?
|
| Retroperitoneal Space | 1 | 2021 | 16 | 0.190 |
Why?
|
| Tissue Extracts | 2 | 2012 | 19 | 0.180 |
Why?
|
| Indazoles | 2 | 2012 | 66 | 0.180 |
Why?
|
| Quality of Life | 4 | 2024 | 2694 | 0.180 |
Why?
|
| Kallikreins | 2 | 2019 | 29 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 153 | 0.180 |
Why?
|
| Retreatment | 1 | 2021 | 70 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 277 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2024 | 374 | 0.170 |
Why?
|
| Time Factors | 5 | 2020 | 6530 | 0.160 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 58 | 0.160 |
Why?
|
| Phosphatidylcholines | 2 | 2013 | 145 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 218 | 0.160 |
Why?
|
| Yttrium | 1 | 2018 | 5 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 305 | 0.160 |
Why?
|
| Euterpe | 1 | 2018 | 4 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2020 | 173 | 0.150 |
Why?
|
| Fluorides | 1 | 2018 | 50 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 32 | 0.150 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.150 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1326 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2020 | 256 | 0.150 |
Why?
|
| Congresses as Topic | 2 | 2012 | 215 | 0.150 |
Why?
|
| Antioxidants | 2 | 2013 | 557 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2021 | 1018 | 0.140 |
Why?
|
| Apoptosis | 1 | 2007 | 2488 | 0.140 |
Why?
|
| Piperidines | 2 | 2010 | 200 | 0.140 |
Why?
|
| Lymph Node Excision | 2 | 2021 | 164 | 0.140 |
Why?
|
| Tumor Escape | 1 | 2018 | 39 | 0.140 |
Why?
|
| History, 21st Century | 2 | 2015 | 186 | 0.140 |
Why?
|
| Genome | 1 | 2020 | 278 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 3 | 2018 | 397 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 164 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2025 | 977 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 121 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2062 | 0.140 |
Why?
|
| Proton Therapy | 1 | 2017 | 12 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2010 | 1199 | 0.130 |
Why?
|
| Goserelin | 3 | 2018 | 7 | 0.130 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 27 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 1087 | 0.130 |
Why?
|
| Mutation | 2 | 2024 | 3702 | 0.130 |
Why?
|
| Aftercare | 1 | 2018 | 206 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2018 | 198 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 2271 | 0.130 |
Why?
|
| Fatal Outcome | 2 | 2008 | 300 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2016 | 67 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2018 | 173 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2018 | 260 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 3392 | 0.130 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 74 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 195 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 486 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 591 | 0.120 |
Why?
|
| Prostate | 2 | 2021 | 170 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 659 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 98 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2018 | 376 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 110 | 0.110 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2014 | 10 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2014 | 35 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2016 | 269 | 0.110 |
Why?
|
| Mitotic Index | 1 | 2014 | 26 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 38 | 0.110 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.110 |
Why?
|
| Carcinoma, Medullary | 1 | 2013 | 13 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2018 | 583 | 0.110 |
Why?
|
| Breeding | 1 | 2013 | 61 | 0.110 |
Why?
|
| beta-Galactosidase | 1 | 2013 | 77 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 325 | 0.110 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 108 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2013 | 143 | 0.100 |
Why?
|
| Geriatrics | 1 | 2014 | 81 | 0.100 |
Why?
|
| Urogenital Neoplasms | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hyperplasia | 1 | 2013 | 175 | 0.100 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 32 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2014 | 437 | 0.100 |
Why?
|
| Keratins | 1 | 2013 | 173 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 3081 | 0.100 |
Why?
|
| Organ Specificity | 1 | 2013 | 296 | 0.100 |
Why?
|
| Nephrectomy | 2 | 2013 | 158 | 0.100 |
Why?
|
| Sirolimus | 2 | 2014 | 270 | 0.100 |
Why?
|
| Integrases | 1 | 2013 | 117 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 376 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2013 | 190 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2012 | 2367 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2015 | 440 | 0.100 |
Why?
|
| Celecoxib | 1 | 2012 | 39 | 0.100 |
Why?
|
| Thyroid Hormones | 1 | 2012 | 55 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1149 | 0.100 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 117 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2012 | 57 | 0.100 |
Why?
|
| Thyroid Gland | 1 | 2012 | 92 | 0.100 |
Why?
|
| Quinolines | 1 | 2013 | 156 | 0.090 |
Why?
|
| Reoperation | 1 | 2014 | 542 | 0.090 |
Why?
|
| Imidazoles | 1 | 2012 | 235 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 522 | 0.090 |
Why?
|
| PubMed | 1 | 2010 | 10 | 0.090 |
Why?
|
| Denosumab | 1 | 2010 | 8 | 0.090 |
Why?
|
| RANK Ligand | 1 | 2010 | 26 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 270 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 20 | 0.090 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2010 | 70 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 38 | 0.080 |
Why?
|
| Vimentin | 1 | 2010 | 51 | 0.080 |
Why?
|
| Cell Separation | 1 | 2011 | 315 | 0.080 |
Why?
|
| Animals | 5 | 2016 | 35334 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 804 | 0.080 |
Why?
|
| Mesoderm | 1 | 2010 | 138 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 76 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 931 | 0.080 |
Why?
|
| Nephrolithiasis | 1 | 2009 | 10 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1235 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 187 | 0.080 |
Why?
|
| Metaplasia | 1 | 2009 | 57 | 0.080 |
Why?
|
| Gynecomastia | 1 | 2008 | 6 | 0.080 |
Why?
|
| Age Factors | 1 | 2016 | 3150 | 0.080 |
Why?
|
| Risk | 1 | 2011 | 857 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 1997 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 424 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 1827 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 2135 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1037 | 0.070 |
Why?
|
| Southwestern United States | 1 | 2008 | 90 | 0.070 |
Why?
|
| Risk Factors | 5 | 2018 | 9779 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 1196 | 0.070 |
Why?
|
| Mediastinal Diseases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 310 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2008 | 66 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 93 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 24 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 525 | 0.070 |
Why?
|
| Pyridines | 1 | 2010 | 478 | 0.070 |
Why?
|
| Glucuronides | 1 | 2006 | 18 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 106 | 0.070 |
Why?
|
| Young Adult | 5 | 2024 | 12438 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2007 | 117 | 0.070 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2006 | 84 | 0.070 |
Why?
|
| Excipients | 1 | 2006 | 52 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2006 | 112 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 107 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 338 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 123 | 0.060 |
Why?
|
| Mice | 2 | 2013 | 16973 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 180 | 0.060 |
Why?
|
| Pedigree | 1 | 2007 | 482 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 798 | 0.060 |
Why?
|
| Everolimus | 2 | 2017 | 88 | 0.060 |
Why?
|
| Sarcoidosis | 1 | 2007 | 157 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 360 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 335 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2016 | 4916 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1422 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 197 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 54 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 65 | 0.060 |
Why?
|
| Cystoscopy | 1 | 2024 | 20 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2010 | 1061 | 0.060 |
Why?
|
| Radiotherapy | 2 | 2015 | 185 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2024 | 708 | 0.050 |
Why?
|
| Melanoma | 1 | 2011 | 728 | 0.050 |
Why?
|
| Biomarkers | 2 | 2023 | 3968 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1050 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2009 | 732 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 157 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 4891 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2020 | 1684 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 4073 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 193 | 0.050 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2021 | 1 | 0.050 |
Why?
|
| Immune System Diseases | 1 | 2002 | 34 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 143 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 94 | 0.040 |
Why?
|
| Prednisolone | 1 | 2021 | 82 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 366 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2002 | 103 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 287 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 353 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2021 | 128 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 84 | 0.040 |
Why?
|
| Proteomics | 1 | 2007 | 1053 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 427 | 0.040 |
Why?
|
| Mass Screening | 1 | 2008 | 1186 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 393 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 292 | 0.040 |
Why?
|
| Ytterbium | 1 | 2018 | 2 | 0.040 |
Why?
|
| Erbium | 1 | 2018 | 5 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2019 | 48 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 244 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 129 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 649 | 0.040 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2018 | 14 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2008 | 3255 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 76 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 147 | 0.040 |
Why?
|
| Lasers | 1 | 2018 | 133 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2023 | 606 | 0.040 |
Why?
|
| Pain | 1 | 2024 | 788 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2021 | 446 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 43 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 398 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 209 | 0.030 |
Why?
|
| DNA | 1 | 2023 | 1400 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 34 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 98 | 0.030 |
Why?
|
| Thoracic Neoplasms | 1 | 2015 | 35 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 200 | 0.030 |
Why?
|
| Nanoconjugates | 1 | 2014 | 1 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 2014 | 13 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 124 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 783 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 614 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 441 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 484 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 129 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2018 | 409 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 429 | 0.030 |
Why?
|
| Benchmarking | 1 | 2015 | 175 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2015 | 169 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 352 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 88 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 350 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2018 | 1735 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 7150 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 133 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 208 | 0.020 |
Why?
|
| Androgens | 1 | 2011 | 177 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 611 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 319 | 0.020 |
Why?
|
| Seizures | 1 | 2012 | 402 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1491 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1966 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 282 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 115 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 82 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20409 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 1084 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 544 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 2643 | 0.010 |
Why?
|